Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Beigene Ltd ADR (NQ: BGNE )

255.05 +0.77 (+0.30%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 2, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Beigene Ltd ADR

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
BeiGene Launches Talk About It Program to Elevate the Importance of Addressing Mental Health during Cancer Care
From BeiGene
Via Business Wire
What 4 Analyst Ratings Have To Say About BeiGene
Analysts have provided the following ratings for BeiGene (NASDAQ:BGNE) within the last quarter: 
Via Benzinga
BeiGene Announces Brazil Approvals for BRUKINSA® As a Treatment for Rare Blood Cancers
From BeiGene
Via Business Wire
Is This Chinese Pharmaceutical Stock Worth the Risk?
BeiGene's shares are down this year, but it has two potential blockbusters. 
Via The Motley Fool
European Heath Agency's Committee Backs Approving BeiGene's Brukinsa In Leukemia Setting
 
Via Benzinga
Analyst Ratings for BeiGene
Analysts have provided the following ratings for BeiGene (NASDAQ:BGNE) within the last quarter: 
Via Benzinga
UK's NICE Recommends BeiGene's Cancer Drug For Rare Form Of Blood Cancer
 
Via Benzinga
Tesla, Amazon, Coupang, Rivian, Beigene: Musk's Share Sale, Antitrust Lawsuit, Earnings Grab Retail Investors' Eyeballs
Major Wall Street indices closed nearly 2% lower on Wednesday after the day was marred by uncertainties including the outcome of the mid-term elections and a sell-off in the cryptocurrency... 
Via Benzinga
BeiGene Reports Third Quarter 2022 Financial Results
From BeiGene, Ltd.
Via Business Wire
BeiGene to Present at Upcoming Investor Conferences
From BeiGene
Via Business Wire
BeiGene to Present Dynamic View of Development Programs for Hematologic Malignancies at 64th ASH Meeting
From BeiGene
Via Business Wire
BeiGene Receives European Commission Approval for BRUKINSA® (zanubrutinib) for the Treatment of Adults with Marginal Zone Lymphoma
From BeiGene
Via Business Wire
BeiGene Expands Reach of its Innovative BTK Inhibitor with Recent Regulatory Approvals in Latin America
From BeiGene
Via Business Wire
Jazz Obtains Exclusive Rights To Zymeworks' Cancer Candidate In Almost $2B Biobuck Deal
 
Via Benzinga
New Drugs Approvals Bring No Relief for Ailing Innovent Bio
Key Takeaways: Innovent Bio has brought several drugs to market in recent years, including two announced last week, but is still losing money with no profits in sight The company has overhauled its... 
Via Benzinga
Week In Review: Jemicare Out-Licenses Prostate Cancer Therapy To Roche For $650 Million
Deals, financings, trials and approvals on the China biotech/pharma market. 
Via Talk Markets
BeiGene Receives Positive CHMP Opinion for BRUKINSA® (zanubrutinib) for the Treatment of Adults With CLL
From BeiGene
Via Business Wire
BeiGene Takes On Johnson & Johnson's Blockbuster Cancer Drug — And Wins
A smaller biotech tested its experimental leukemia drug against J&J's approved med. 
Via Investor's Business Daily
BeiGene's Brukinsa Shows Superior Progression-Free Survival Versus JNJ's Treatment
 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 13, 2022
Upgrades 
Via Benzinga
BeiGene Announces Positive Topline Results from Final Progression-Free Survival Analysis of BRUKINSA® (zanubrutinib) Compared to IMBRUVICA® (ibrutinib) in Phase 3 Chronic Lymphocytic Leukemia (CLL) Trial
From BeiGene
Via Business Wire
NICE Recommends BeiGene’s BRUKINSA® (zanubrutinib) for Patients with Waldenström’s Macroglobulinemia who have had at Least One Treatment
From BeiGene
Via Business Wire
BeiGene Receives Positive CHMP Opinion for BRUKINSA® (zanubrutinib) for the Treatment of Adults with Marginal Zone Lymphoma
From BeiGene
Via Business Wire
BeiGene's Tislelizumab Shows Non-Inferiority In Overall Survival, Safety Vs Standard Treatment In Solid Tumors
 
Via Benzinga
BeiGene Announces Data Presentations at ESMO 2022 Including Late-Breaking Oral Presentation for Tislelizumab in First-Line Unresectable Hepatocellular Cancer
From BeiGene
Via Business Wire
Junshi Biosciences Hits Revenue Roadblock Amid Covid Drug Delay
Key Takeaways: The company logged a revenue fall of 55% in the first half of the year and posted a loss of $131 million Phase 3 clinical trials for its Covid-19 oral drug wrapped up in May but the... 
Via Benzinga
BeiGene to Present at the Morgan Stanley 20th Annual Global Healthcare Conference
From BeiGene
Via Business Wire
U.S.-China Audit Deal Won't Slow Hong Kong Dual Listing Train, Analysts Say
Key Takeaways: Despite a landmark U.S.-China information-sharing agreement, some predict dual listings in New York and Hong Kong will remain the preferred choice for Chinese... 
Via Benzinga
7 Chinese Stocks to Sell While You Still Can
These Chinese stocks have had a rough outing at the stock markets of late, as their underlying businesses buckle under the economic pressure 
Via InvestorPlace
Why Bed Bath & Beyond Jumped Around 25%; Here Are 68 Biggest Movers From Yesterday
Gainers 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.